Pharmaspire
× About the Journal Scope of the Journal SPER Publications Editorial Board Abstracting and Indexing Articles in Press Current Issue Archives Submit Article Author Guidelines Advertise Join as Reviewer Contact Editorial Policies and Peer Review Process Journal Policies Publishing Ethics


 

Original Article
Year : 2020   |  Volume : 12  |  Issue : 3  |  Page : 96-99

Nasal mucoadhesive thermoreversible in situ gel of phenytoin sodium for epilepsy

Introduction: The aim of the present study was to formulate and characterize nasal mucoadhesive thermoreversible in situ gel of phenytoin sodium for the treatment of Epilepsy. Procedure: The in situ gel was prepared by cold method using thermoreversible polymer Pluronic F127, polyethylene glycol 4000, and propylene glycol which would enhance nasal residence time, absorption of drug across nasal-mucosal membrane, improve bioavailability, and dose reduction. The in situ gel was characterized in terms of gelation temperature, gelation time, pH, viscosity, drug content, mucoadhesive strength, and percentage cumulative release. Results: The gelation temperature and gelation time of the various formulations were found to be in the range of 28–38°C and 90–164 s, respectively. The pH was found to be in the range of 5.9–6.8. Mucoadhesive strength of various formulations was found to be between 47.032 and 126.775 g. The cumulative percentage release of phenytoin sodium from various formulations was found to be in the range of 39.2–53.2%. Conclusion: The formulated phenytoin sodium in situ gel is an ideal vehicle for specific treatment of epilepsy. Sustained and prolonged release of the drug, good stability, and biocompatibility characteristics make the in situ gel dosage forms reliable.
[]*
Print this article     Email this article